Hubei Biocause Heilen Pharmaceutical Co., Ltd.
301211.SZ · SHZ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | CN¥4,222 | CN¥4,331 | CN¥5,734 | CN¥6,224 |
| - Cash | CN¥543 | CN¥1,694 | CN¥1,858 | CN¥1,860 |
| + Debt | CN¥19 | CN¥5 | CN¥7 | CN¥30 |
| Enterprise Value | CN¥3,698 | CN¥2,642 | CN¥3,883 | CN¥4,394 |
| Revenue | CN¥446 | CN¥663 | CN¥515 | CN¥541 |
| % Growth | -32.8% | 28.8% | -4.8% | – |
| Gross Profit | CN¥129 | CN¥266 | CN¥149 | CN¥182 |
| % Margin | 28.8% | 40.2% | 28.9% | 33.7% |
| EBITDA | CN¥126 | CN¥225 | CN¥170 | CN¥159 |
| % Margin | 28.3% | 34% | 33% | 29.4% |
| Net Income | CN¥92 | CN¥176 | CN¥126 | CN¥122 |
| % Margin | 20.5% | 26.6% | 24.4% | 22.5% |
| EPS Diluted | 0.32 | 0.61 | 0.44 | 0.42 |
| % Growth | -47.5% | 38.6% | 4.8% | – |
| Operating Cash Flow | CN¥96 | CN¥137 | CN¥251 | CN¥124 |
| Capital Expenditures | -CN¥164 | -CN¥187 | -CN¥76 | -CN¥21 |
| Free Cash Flow | -CN¥68 | -CN¥49 | CN¥175 | CN¥103 |